The Internal Revenue Service has issued guidance to manufacturers and importers of branded prescription drugs on the annual fee imposed by the health care law.
Notice 2010-71 provides guidance regarding the annual fee imposed by Section 9008 of the Patient Protection and Affordable Care Act on manufacturers and importers of branded prescription drugs that sell these drugs to or pursuant to coverage under Medicare Part B and D programs, Medicaid, the Department of Veterans Affairs, the Department of Defense, and TRICARE.
